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Abstract
Objectives. The paediatric idiopathic inflammatory myopathies (IIMs) are a group of rare chronic inflam-
matory disorders of childhood, affecting muscle, skin and other organs. There is a severe lack of evidence
base for current treatment protocols in juvenile myositis. The rarity of these conditions means that multi-
centre collaboration is vital to facilitate studies of pathogenesis, treatment and disease outcomes. We
have established a national registry and repository for childhood IIM, which aims to improve knowledge,
facilitate research and clinical trials, and ultimately to improve outcomes for these patients.
Methods. A UK-wide network of centres and research group was established to contribute to the study.
Standardized patient assessment, data collection forms and sample protocols were agreed. The Biobank
includes collection of peripheral blood mononuclear cells, serum, genomic DNA and biopsy material. An
independent steering committee was established to oversee the use of data/samples. Centre training was
provided for patient assessment, data collection and entry.
Results. Ten years after inception, the study has recruited 285 children, of which 258 have JDM or
juvenile PM; 86% of the cases have contributed the biological samples. Serial sampling linked directly
to the clinical database makes this a highly valuable resource. The study has been a platform for 20 sub-
studies and attracted considerable funding support. Assessment of children with myositis in contributing
centres has changed through participation in this study.
Conclusions. This establishment of a multicentre registry and Biobank has facilitated research and
contributed to progress in the management of a complex group of rare muscloskeletal conditions.
Key words: Juvenile myositis, Dermatomyositis, Idiopathic inflammatory myopathy, Paediatric, Registry,
Biobank, Multicentre.
Introduction
The idiopathic inflammatory myopathies (IIMs) are a het-
erogeneous group of disorders that have in common a
chronic autoimmune inflammatory process affecting vari-
ably muscle, skin and internal organs [1]. The childhood
IIMs include JDM, juvenile PM (JPM) and other, less
common, disorders [2, 3]. The incidence of JDM is 2–
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E3/millions/year, with some differences between the ethnic
groups [4–8]. The rarity of these conditions means that
very few single centres have sufficient patient numbers
to adequately power the studies of disease complications,
outcomes or response to treatment.
The clinical manifestations of the IIMs differ between
children and adults, and the various disease types occur
with differing frequencies. In childhood, DM occurs far
more frequently than PM, whereas in adults the ratio is
more equal. Other forms of myositis, such as IBM, are
very rare in the paediatric population. Severe complica-
tions of DM, such as vasculopathic ulceration and calci-
nosis, are more common in juvenile than adult-onset
disease, and overlap syndromes with features of other
connective tissue disorders occur more commonly [6–9].
Despite considerable advances in the management of
childhood IIMs, the conditions are still associated with
significant morbidity and mortality, representing a major
long-term medical, social and economic burden on
patients, their families and health care systems [10].
Evidence suggests that early aggressive management of
JDM improves outcome, whereas a long duration of un-
treated disease is associated with longer time to reach re-
mission and higher rates of complications such as ongoing
skin disease or functional impairment [11–13]. Emerging
data suggest an increased risk of morbidities, such as
cardiovascular disease, and osteoporosis in adulthood
although few long-term outcome data are yet available.
Improving both long- and short-term outcomes requires
early recognition, prompt referral to specialist care and
appropriate treatment of patients with JDM and other
forms of myositis. These goals have been hindered by
the lack of an evidence base in paediatric myositis. Little
is known about the basic mechanisms underlying the
pathogenesis of childhood myositis, and there is almost
no level 1 evidence base from trials in JDM for any specific
therapeutic interventions that are in current use. There is,
therefore, an urgent need for robust basic, translational
and clinical research in this field and the generation of
standardized protocols of management. Until recently, it
was difficult to carry out detailed investigations of genet-
ics, disease mechanisms or biomarker studies, let alone
clinical trials, in the paediatric IIMs due to their rarity, the
lack of validated tools for the assessment of disease ac-
tivity or outcome and the absence of any standardized
treatment protocols.
Here, we present the 10-year experience of the
Juvenile Dermatomyositis National (UK and Ireland)
Cohort Biomarker Study and Repository for Idiopathic
Inflammatory Myopathies, formerly known as the Juvenile
Dermatomyositis National (UK and Ireland) Registry and
Repository for Idiopathic Inflammatory Myopathies. The
aims of this registry are to define the clinical character-
istics, biomarkers and response to treatments of childhood
IIMs, while at the same time developing the specific infra-
structure and tools needed to enable participation in
interventional trials (Table 1). Through the generation of
standardized protocols for investigation and management,
this study aims to make significant and important contri-
butions to the recognition, understanding and manage-
ment of paediatric myositis, and so to address the needs
of children with these severe, life-threatening diseases.
Methods
The establishment of a national registry and repository for
childhood IIMs [the Juvenile Dermatomyositis National
(UK and Ireland) Cohort Biomarker Study and Repository
for Idiopathic Inflammatory Myopathies] was made pos-
sible following an initial generous grant from the C. Hayes
Research Trust. The study was launched in 2000 and to
date has recruited 285 children.
Establishing the network of centres and
research group
The coordinating centre, based at UCL Institute of Child
Health, London, initiated discussions with the British
Society of Paediatric and Adolescent Rheumatology
requesting expressions of interest from units wishing to
contribute to the registry. Units deemed able to recruit
adequate numbers of patients (regional tertiary paediatric
rheumatology referral centres) were offered funding for
allied health professional/research nursing sessions to
recruit patients, and undertake data entry and sample
collection. Central to the success of the registry was a
series of initiating visits to participating centres offering
discussion about practicalities of recruitment, form com-
pletion, use of validated assessment tools for muscle
function and disease activity [including the childhood
myositis assessment scale (CMAS) and manual
muscle testing (MMT)] [14–17] and protocols for sample
collection.
TABLE 1 Aims of the UK JDM cohort biomarker study and repository
Determine the demographics of JDM
Define disease presentation, activity, damage, current management protocols and response to current medication use
Determine prognostic biomarkers (genetic, serological, gene expression or others)
Assess the validity and reliability of disease activity scores that can be used in the clinical assessment of response to
therapy as well as future clinical trials
Develop a cohort of patients suitable for recruitment to clinical interventional trials
Facilitate national and international collaborative research studies and trials in JDM
Create a consented repository of data and sample collection to investigate the immunological and genetic abnormalities
of JDM with a view to identifying future therapeutic targets
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Neil Martin et al.Ethical approval was obtained for collection of data and
biological samples within the Biobank, and the study was
carried out in accordance with the Declaration of Helsinki.
Patients and families are fully aware that consent includes
donation of the contributed biological material. A separ-
ate, broad ethical approval was obtained, for the use
of the Biobank samples in the investigation of the patho-
genesis of childhood myositis. The group of committed
researchers was formally established as the Juvenile
Dermatomyositis Research Group (JDRG), ensuring
ownership of, and commitment to, the project. An inde-
pendent steering committee was established, including
external clinical, ethical and scientific advisors, and con-
sumer representation, to oversee the project and scrutin-
ize applications to use the clinical data and/or biological
samples from the registry/repository. Authorship and
membership guidelines were agreed, and a standardized
application process and agreement forms for access to
data or samples developed, for use by external
collaborators.
Recruitment, data entry and sample Biobank
Data collection forms were developed through a series of
consensus meetings using the nominal group technique
with the principle investigators (PIs) and members of the
research teams. Agreement was reached regarding key
typical and less common clinical features to be recorded.
A standardized set of assessments, including those for
muscle function strength and stamina, and laboratory in-
vestigations were agreed. Baseline and follow-up forms
were developed, recording history, clinical features,
muscle assessment, laboratory results and details of
treatment. Annual incidence figures provided an estimate
of 20–30 new cases a year within the UK. Given this rarity
of both JDM and other paediatric IIMs, it was agreed to
recruit both established cases (i.e. including data obtained
retrospectively) and new cases, recruited at diagnosis.
Contributing centres were all referral centres for specialist
paediatric rheumatology care but were encouraged to
facilitate recruitment from, and shared care with, other
clinicians and hospitals locally, using established net-
works of care. This both increased recruitment of patients
to the registry and provided a mechanism for dissemin-
ation of the best practice. All patients included have given
written informed parent/patient consent/assent.
A central database was established, with full technical
support, and maintained by a dedicated data manager,
who also provides support to local centres. All data are
anonymized. During the first 10 years of the registry, data
have been collected on paper forms and entered onto the
database at the coordinating centre. Work is ongoing to
develop web-based data entry, which should minimize the
need for data entry centrally saving both time and poten-
tial transcription errors. Paper data collection will remain
an option for any unit unable to enter online. The Biobank
of clinical samples has been integral to the study through-
out, meaning that this is now a unique resource, with sam-
ples stored from the time of presentation and during the
disease course. In accordance with ethical approval for
paediatric studies, venous blood is collected only when
venepuncture is clinically indicated, and sent to the coor-
dinating laboratory to be processed. Peripheral blood
mononuclear cells (PBMCs), serum and genomic DNA
are prepared and stored following agreed standard oper-
ating procedures using standard methods. One centre on
site with the coordinating laboratory can complete sample
processing within 4h of venepuncture and also, therefore,
stores plasma samples for proteomics. Biopsy material is
stored (after diagnostic work has been completed) in
cases on whom muscle or other biopsy is performed.
Results
Membership of the JDRG network
Nine centres originally agreed to participate in the JDRG.
All PIs have had specialist training in paediatric rheuma-
tology and work in specialist referral centres for paediatric
rheumatology. The full contributor list is provided in the
acknowledgements. An indication of the success of this
registry is that all original centres recruiting and contribut-
ing data to the registry continue to do so, and several new
centres wishing to join have recently approached the
coordinating centre. New centres are provided with
specific training before starting to recruit patients.
Data and sample collection
Fundamental to the establishment of the registry was
agreement by consensus on a core set of data and the
development of standardized forms for this collection
(see supplementary data Forms 1 and 2, available at
Rheumatology Online). Data are collected at recruitment
(Form 1) including information on disease up to the date of
recruitment and then serially (Form 2), with 3–4 monthly
data for the first 2 years and then at least once a year. For
the latter, annual data summing 1 year are now collected
onto a separate form (see supplementary data Form
3, available at Rheumatology Online). Together with
common and rarer symptoms and examination features,
data collection includes assessment of disease activity
using the following tools: CMAS, MMT of strength,
Childhood HAQ (CHAQ), physician’s global assessment
by visual analogue scale (VAS), parent/patient assess-
ment by VAS and laboratory tests (Forms 1 and 2).
These measures are all part of the recent proposed core
sets of measures to measure disease activity in JDM and
the CMAS, MMT and CHAQ are all validated tools in JDM
[14–17]. Clinicians familiar with the data collection forms
are able to complete Forms 1 and 2 in 10min. Some
contributors use Form 2 as their clinical record, reducing
the burden of additional time for form filling. Biobank sam-
ples are stored, as a minimum, at recruitment (serum,
DNA and PBMCs), and then serum (and DNA where
required) on an annual basis, whereas PBMC samples
are stored at baseline, 1 and 5 years. Biopsy material
has been successfully sent from many centres around
the country, either a frozen block of tissue or as fixed
dried slides ([18] and J. Holton, V. Varsani and L.R.
Wedderburn, submitted).
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National registry for JDMRecruitment and patient demographics
To be eligible for the study, a child must have definite or
suspected myositis with symptoms starting before the
16th birthday. This cut-off age reflects current UK clinical
practice for defining paediatric myositis. Conditions pre-
senting primarily with myositis were considered eligible,
resulting in the inclusion of a number of children with un-
usual diagnoses. Children were approached to enrol in the
study sequentially from all sites, and were included if they
had a diagnosis of definite, probable or possible JDM or
PM as defined by the contributing physician [2, 3]. Since
there are no agreed international criteria for the definition
of overlap syndromes in children, and features of overlap
vary between cases, children with DM or PM, who also
had significant overlap with scleroderma, polyarthritis
lupus or MCTD (provided myositis was the predominant
clinical feature), were recorded as entered by the contri-
buting physician. Other forms of myositis such as focal,
eosinophilic, orbital, inclusion body or sarcoid myositis, or
other IIMs were included. The only exclusion criterion was
entry onto another registry.
In 10 years of the study, 296 patients from nine centres
were approached as eligible for the study, of which
285 were recruited. Four children were subsequently
shown not to have myositis as a primary diagnosis, five
patients had insufficient data for analysis or were lost to
follow-up and one family requested to be removed from
theregistry.Therefore,analysisispossibleon275patients,
of which 175 (63.6%) were recruited prospectively, within
12 months of onset. There have been three deaths of pa-
tients within the registry. From the 275 cases recruited,
86% have contributed blood samples and 81 (29%) have
contributed muscle biopsy material to the Biobank. Our
estimate of the prevalence of JDM in the UK, based upon
incidence and national population data in 2000, was
450 children: it is, therefore, apparent that a percentage
of cases have not yet been reached through our network. It
was hoped that each regional centre would facilitate re-
cruitment from smaller centres and colleagues in other
specialties (dermatology and neurology), to ensure a truly
representative spectrum of patients. In practice, recruit-
ment has largely remained within major centres and the
less severely affected children may, therefore, be under-
represented in the cohort.
The diagnoses assigned to all 275 cases are shown in
Table 2. Demographic and baseline clinical data for the
258 patients with a diagnosis of definite or probable JDM,
and definite or probable JPM are shown separately. JPM
was diagnosed in only seven (2.5%) children in this
cohort. Of the cases assigned with a diagnosis of JDM,
35 had features of overlap with either scleroderma (19),
lupus (7), MCTD (5) or severe arthritis (4). As these overlap
cases were noted at the discretion of the recruiting phys-
ician they may not reflect the overall prevalence of overlap
features within the registry cohort. We have previously
published data outlining the frequency of clinical features
such as arthritis (36%) or features suggestive of sclero-
derma overlap (24%), for patients within the registry [6,
19]. Of the 258 children with a diagnosis of probable or
definite JDM or JPM, 182 (70.5%) were girls, giving a
female to male ratio of 2.39:1. The median age of onset
was 6.3 years, similar to other large cohorts [10, 20–22]. At
disease onset, 37% patients were 44 years old. The dis-
tribution of age of onset is illustrated in Fig. 1. Median time
between onset of symptoms and diagnosis was 4 months.
It is noteworthy that 117 (42%) children had muscle
biopsy but only 21 (7.6%) had an EMG during diagnostic
work-up. This is in keeping with our previous study, which
TABLE 2 Demographics of patients in the registry
(analysis of 275 patients)
a
Diagnosis n (%)
Definite JDM 203 (73.8)
Probable JDM 48 (17.5)
Definite JPM 4 (1.5)
Probable JPM 3 (1.1)
Other IIMs
b 4 (1.5)
Focal myositis 5 (1.8)
MCTD 8 (2.9)
Demographic
data, n (%)
In cases of definite
or probable JDM
or JPM (n=258)
Sex
Girls 182 (70.5)
Boys 76 (29.5)
Ethnicity
White 207 (80.2)
Black—Caribbean 9 (3.5)
Black—African 7 (2.7)
Black—Other 4 (1.6)
Indian 6 (2.3)
Pakistani 10 (3.9)
Bangladeshi 1 (0.4)
Chinese 0
Other ethnicity 14 (5.4)
Baseline characteristics, cases of definite or
probable JDM or JPM
Age at onset, median (IQR),
years
6.3 (3.8–9.6)
Time between symptom onset
and diagnosis, median (IQR),
months
4 (2–10)
Physician’s global assessment
at the time of diagnosis,
median (IQR)
c
4.8 (2.4–7.0)
CHAQ at the time of diagnosis,
median (IQR)
c
1.375 (0.625–2.375)
CMAS at time of diagnosis,
median (IQR)
c
31 (17–47)
aMedian length of completed follow-up data=3.0 years,
IQR=1.1–5.0 years.
bThese four cases were: two brothers
with neonatal-onset multi-system inflammatory disorder that
included prominent inflammatory myositis, one post-
streptococcal myositis and one viral myositis.
cFor those
recruited prospectively where baseline measure at the time
of diagnosis is available. IQR: interquartile range.
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with JDM, and showed that 70% of centres had access to
muscle MRI, but only 61 and 55%, respectively, used
muscle biopsy and EMG in the investigation of children
with suspected myositis [23]. This study and our data con-
firm the need for developing improved diagnostic criteria
based on modern methods of diagnosis.
Funding and research studies resulting from the
Juvenile Dermatomyositis National (UK and Ireland)
Cohort Biomarker Study and Repository for
Idiopathic Inflammatory Myopathies
The initial establishment of this study was made possible
by a grant from the C. Hayes Research Trust. Since that
time the study has attracted considerable research fund-
ing, some for specific projects using the Cohort study as a
platform and others for infrastructure support. These in-
clude grants from the Wellcome Trust, Myositis Support
Group, UK, Raynaud’s and Scleroderma Association,
Arthritis Research, UK (formerly Arthritis Research
Campaign) and Action Medical Research. Recently, the
study has been adopted onto the UK Government-
funded Medicines for Children Research Network port-
folio, making it eligible for UK government-sourced
funding for support for health service research costs. A
dedicated website for public and researcher information
about the study and the JDRG has been launched (www
.juveniledermatomyositis.org.uk).
In the 10 years since inception, the JDM cohort bio-
marker study and repository has generated 20 specific
projects (Table 3), led both by members of the JDRG
and by outside investigators, and agreed by the Steering
Committee. Many of these have generated new know-
ledge, including pathological studies [24–30], generation
of a standardized assessment of muscle biopsy [18], ima-
ging studies [31], a study on the effects of exercise on MRI
features in muscle [32], characterization of novel auto-
antibodies in JDM [6, 33, 34], serological/genetic correla-
tive studies and candidate gene association studies
[6, 35, 36]. In addition, the study has generated analysis
of our initial large cohort of children with myositis [19] as
well as specific studies focusing on complex cases such
as children with orophayrngeal involvement [37] and the
use of novel therapies [38, 39]. Further clinical and basic
studies are ongoing.
In line with our goals, the resource and expertise facili-
tated through this Cohort study and the JDRG have led
to numerous collaborative efforts. These include an
international survey on diagnostic methods in JDM [23],
contributions to studies to generate disease activity and
damage measures [40, 41], long-term outcome studies in
JDM [10], consensus-driven protocols [42] and ongoing
involvement in other national and international projects.
The JDRG and its members are closely involved in
the JDM strategy of the UK Clinical Studies Group
for paediatric rheumatology (www.mcrn.org.uk), contribu-
tion to ongoing clinical trials, and in the International
Myositis Assessment and Clinical Studies Group
(IMACS), European Myositis Network (EUMYONET) and
International Myositis Genetics Consortium (MYOGEN).
Genetic studies have included a large contribution from
this cohort to a world-wide collaborative effort to carry out
a genome-wide association study of myositis.
Effects of the Juvenile Dermatomyositis Cohort
Biomarker Study and Repository for Idiopathic
Inflammatory Myopathies on clinical practice
In addition to the ongoing research studies on juvenile
myositis, there is evidence that the use of our study
data forms has led to a more standardized approach for
the assessment of affected children (N.M., unpublished
data). The decision to include the CMAS as part of the
standard assessment and the training provided during
setting up of the registry have led to its widespread adop-
tion as a reliable clinical tool for the assessment of muscle
strength in units around the UK. The establishment of the
JDRG has provided a forum for regular communication
between members, and facilitated discussion regarding
treatment approaches. There is emerging evidence that
this has led to a gradual shift in practice from the initial
cohort [19] to the present day. Treatment of JDM is not yet
evidence based but the group has facilitated emerging
consensus. Standardized treatment protocols are cur-
rently under discussion and will hopefully be adopted by
the group, providing a more secure basis for assessing
outcome and the basis of future therapeutic studies.
Discussion
The establishment of this registry and repository of bio-
logical samples from children with juvenile IIMs has pro-
vided a unique opportunity and resource with which to
improve our knowledge and understanding of these rare
childhood disorders. The cohort is now of a size to allow
studies of long-term morbidity and outcomes. Several
other registries and large cohort studies of JDM have
been described [7, 10, 20–22, 43], but to our knowledge
this is one of the very few multicentre studies to include
serial clinical data, the majority collected prospectively,
directly linked to serial biological sampling. This will
FIG.1Age distribution at onset of myositis symptoms in
the 258 children recruited to the Juvenile Dermatomyositis
National (UK and Ireland) Cohort Biomarker Study and
Repository for Idiopathic Inflammatory Myopathies, with
definite or probable JDM or definite or probable JPM.
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National registry for JDMallow testing of biomarkers and their predictive potential:
such studies are underway. Our cohort has similar demo-
graphics to previously described cohorts. The majority of
children were diagnosed within a relatively short time of
disease onset (median time to diagnosis 4 months). This
could reflect a bias in that children on the registry repre-
sent those who are cared for in regional paediatric
rheumatology centres. Three deaths within this cohort
give a mortality rate of 1%; however, we are aware that
this may be an underestimate if some children who pre-
sented with very severe disease died before being
recruited to the study.
The development of this project posed many chal-
lenges, some foreseen, others not. There have also been
unanticipated opportunities and benefits. Generous
start-up funding was pivotal to the initial successful estab-
lishment of the registry. Funding to enable dedicated staff
time in both the coordinating and local recruiting centres
was important. Perhaps the most crucial factor in the suc-
cess of this project was the early establishment of own-
ership and inclusive membership within the group.
Ensuring that all centres benefited from the initial funding,
visits from the coordinating centre team to each unit and a
significant amount of time spent on a consultation process
to define the data collection has engendered a sense of
collective responsibility for the project. The inclusion of all
centres into an inclusive research group, the JDRG, and
ensuring that the Chair of the Steering Committee was not
from the coordinating centre were helpful. The success of
this approach is perhaps best reflected in the fact that
centres have subsequently continued to contribute data
and samples without dedicated funding.
In keeping with many similar registry projects and non-
hypothesis-driven research, defining the correct data set
was a significant challenge. It may only be once the
projects are underway that the superfluous or missed
data items become apparent. In this project it was only
once the work had begun to study specific antibodies that
differed between children with overlap conditions and
‘pure’ JDM, that it was realized that the initial data set
failed to capture the presence or absence of Raynaud’s
symptoms, crucial for clinical characterization for this sub-
study [6]. This necessitated going back to the recruiting
units for further information and the data set was
subsequently amended. Similarly, it is clear that there
are items of redundant data within the registry and sim-
plifying the collection with a single annual follow-up form
has subsequently been agreed by the group. Although it is
desirable to maintain a constant data set throughout, it is
also important to be able to retain some flexibility to revise
this if necessary. A major challenge for this registry has
been the inclusion of a large amount of data collected
retrospectively on patients with JDM. In such an uncom-
mon condition it was felt important to include all the cases
and not only new ones on whom data can be gathered
prospectively. It was recognized that this would inevitably
TABLE 3 Projects approved for study within the registry, 2000–10
Year
approved Project title References
2002 Immunological characterization of the infiltrate in JDM muscle [22, 25]
2002 Tracking of lymphocyte changes before or after flare of active disease
2002 Analysis of MHC Class 1 expression in an animal model of myositis [27, 28]
2002 Recognition of MHC Class 1 molecules on muscle cells by lymphocytes
(CD8 T cells or NK cells)
[22, 25, 29]
2002 The role of muscle ultrasound and MRI in juvenile dermatomyositis [30, 31]
2004 Investigation of alterations of MRP8/14 proteins in juvenile dermatomyositis Ongoing study
2004 Autoantibodies and HLA haplotypes in juvenile dermatomyositis,
juvenile scleroderma and overlap syndromes
[8, 32, 33]
2004 Do functional gene variants in anti-inflammatory pathways alter the
course of disease and allow greater inflammatory response?
[34, 35]
2005 Design and testing/validation of a score tool for assessing severity in JDM [29]
2005 Fetuin-A and calcinosis in juvenile dermatomyositis [26]
2005 Genotyping analysis in JDM for phenotype–genotype correlation [8, 34, 35]
2006 Is there evidence of maternal microchimerism in muscle biopsies from children with
juvenile dermatomyositis?
Ongoing study
2006 Extension for genotyping analysis in JDM for phenotype: genotype correlation [35]
2008 Genome-wide association study of the idiopathic inflammatory myopathies
(collaboration with MYOGEN consortium)
Ongoing study
2008 Vasculopathy of JDM Ongoing study
2009 Fatigue in children with juvenile dermatomyositis Ongoing study
2009 A survey of current practice in treatment of juvenile dermatomyositis
in the UK and Ireland
Ongoing study
2009 Development of classification criteria for the idiopathic inflammatory myopathies and
their major subgroups (collaboration with IMACS)
Ongoing study
2009 Five year single blind, phase III effectiveness randomized actively controlled clinical trial
in new onset juvenile dermatomyositis: prednisolone versus prednisolone plus
cyclosporin A versus prednisolone plus methotrexate (collaboration through PRINTO)
Ongoing study
2010 IMACS Outcomes Repository (collaboration with IMACS) Ongoing study
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Neil Martin et al.result in the inclusion of many cases with incomplete data
and that some projects or analyses would only be pos-
sible with the prospectively recruited cases. All cases can
contribute valuable numbers to large genetic studies to
identify susceptibility loci for myositis, even if recruited
retrospectively.
This registry has been highly successful in generating
projects and publications contributing to our body of
knowledge about these rare disorders. It has also drawn
together a group of dedicated researchers, facilitating
their collaboration with larger international projects.
Since its inception, the group, and the data it has col-
lected, have contributed to various large international pro-
jects aiming to define and validate core set measures of
disease activity and damage in JDM and outcome studies
[40, 41, 44]. Although our data set does not formally docu-
ment these core set measures, the individual components
of the tools were already collected as part of the data set,
and therefore available for study. The inclusion of bio-
logical samples from all cases has made possible genetic
and biological studies, in collaboration with investigators
successfully obtaining funding and steering committee
permission for their project. An unexpected benefit from
the establishment of the registry has been the effect of
standardizing data collection and the use of the CMAS
to assess muscle function as routine clinical practice
within the group. The CMAS has been validated for JDM
but was not previously in widespread use in UK centres.
The collaboration has facilitated discussion about treat-
ment and a move to the more widespread use of earlier
more aggressive therapy. It is hoped to build on this ex-
perience and establish standardized treatment protocols,
which would enable further outcome studies.
Lessons learned during the establishment of this regis-
try and Biobank are applicable to other similar projects.
Key to the success of any such project is the establish-
ment of collective ownership by all contributors. The initial
time taken to establish the data collection should not be
underestimated. Researchers and funding agencies
should be aware that it may take several years and a sig-
nificant investment of both time and money before such a
project will become productive.
Rheumatology key messages
. Multicentre collaboration is vital to improve under-
standing of pathogenesis and treatment response in
rare diseases.
. The UK and Ireland JDM registry has supported
clinical and basic research into childhood myositis.
. The UK and Ireland JDM registry and JDM
Research Group have facilitated consensus building
regarding treatment of childhood myositis.
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